Leigh Purvis, MPA

Director, Health Services Research AARP Public Policy Institute



Looking Forward: A Value-Based Approach to Drug Pricing





How do consumers define value?

Great question!

What sounds good on paper may change once it's personal

Reminder: the goal is to get away from status quo





What are some general guidelines for defining value?

 Cannot be simply foisted on public; process must include opportunities for input from wide range of stakeholders

Must be evidence-based; cost alone is an inadequate indicator

Must include a meaningful response to inevitable access concerns





So what's standing in our way?

(See previous slides)

- Information gap(s)
 - Do we have the data we need to link drug prices and value?

- Resources
 - Who is going to perform this work and who is going to pay for it?



What else is needed?

- More research
 - Lessons learned from other countries
 - Is it possible to assess value for all drugs?
 - Is this the best path forward?

- More solutions
 - Value is not a panacea; a valuable drug can still be unaffordable
 - Must address pricing to avoid building on a broken system



